Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal

Executive Summary

UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870

You may also be interested in...

Pfizer Considering Biotech Acquisitions; “Probably No” Big Mergers

Pfizer is returning to acquisition mode, but with an eye on building its biotechnology presence rather than another major pharmaceutical merger

Pharmacia R&D Head Ando Leaves For Celltech; Will Still Work With Pfizer

Pharmacia R&D President Goran Ando, MD, will move to the other side of a partnership between Pharmacia and Celltech for the Phase III rheumatoid arthritis agent CDP-870 as Celltech CEO

Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy

Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts